ReviewDigestion2026
Endoscopic Treatment for Early Barrett's Neoplasia: A Western Perspective.
Review in Digestion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBarrett's oesophagus (BE) is the sole established precursor to oesophageal adenocarcinoma, with striking contrasts in its epidemiology and management between the East and the West. SUMMARY: This review, based on a structured literature search, examines the key divergences in endoscopic management: highlighting the Western emphasis on eradication therapy using ablation techniques such as radiofrequency ablation, contrasted with the Eastern expertise in advanced resection techniques including endoscopic submucosal dissection. KEY MESSAGES: Despite improving patient outcomes, significant challenges remain, including variable surveillance protocols, controversies regarding non-dysplastic BE and low-grade dysplasia, and optimal strategies for recurrent disease. As gastroesophageal reflux disease and long-segment BE rise in prevalence in the East, and Western proficiency in endoscopic submucosal dissection grows, these once-distinct approaches are poised to converge. As these treatment paradigms align, patients and clinicians alike stand to benefit from more effective, tailored care and better long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.